Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Bactiguard, Audiocast with teleconference, Q2'24

By Inderes7/16/2024, 9:00 AM
Bactiguard

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Christine Lind
00:00 - 11:24

Thank you, Operator, and welcome to the presentation of Bactiguard's Q2 2024 report. I will go through the presentation together with our CFO, Patrick Bach, and open up for questions towards the end. Thank you all for dialing in today. I have just completed my third month as CEO of Bactiguard, and my reflection from this time is that we have a lot of the building blocks in place to execute on our new strategy. We have been through a transformation. However, the team in place is very experienced and highly motivated to make the world a healthier place. While we still have transitional activities, from the transformation to complete throughout the remainder of 2024, we are one team collaborating closely together with a solution-oriented approach and a performance mindset. Now turning to the developments of the second quarter. Let me start with the figures on an overall level. Our total revenues for Q2 amounted to $60.9 million, an increase of almost 19% compared to the same period last year. And for the first half to 119.7 million, which was an increase of 6.5% versus last year. Our license revenues are stabilizing thanks to our good partnerships with BD and Zimmer Biomet. We also report a positive EBITDA for 2024. Our EBITDA came in at 1.2 million SEK for the quarter, and net -0.3 million SEK for the six-month period. Patrick will dig deeper into the financials later in the presentation, but I want to note that we have embarked on our path towards profitability, and I am cautiously optimistic while realizing that we still have a lot to deliver. As for the highlights of the quarter, I assumed my role as CEO in April, and at the annual general meeting in May, Thomas von Koch was re-elected as chair of the board. In addition to Thomas, we are privileged to have the board that we do, supporting Bactiguard with relevant experience and knowledge, both from our industry and the medical sphere, as well as in growing profitable companies. Another important theme from the quarter is the expansion of Bactiguard coated products to new markets with BD, but also with Zimmer Biomet, including the introduction of Bactiguard in Japan. I will come back to that shortly. In July, we strengthened the organization with the appointment of Nathaniel Bachrach as interim head of R&D, and he is now a part of the Bactiguard executive management team. Tony is a product development executive with more than 25 years of experience in innovating, developing, and launching advanced medical products for global commercialization. He has been executive vice president and chief scientific officer at 3DBio Therapeutics, and previously Vice president, Research and Technology at LifeCell Corporation, where we served together on the LifeCell Leadership Team. Prior to that, he held various leadership and technical roles within LifeCell and Organogenesis Inc. Tony holds a PhD in Mechanical Engineering and Biomechanics and has an impressive record of publications and innovative patents. He is based in New Jersey in the US, and will spend his time driving our R&D strategy and in new business development. We are all excited to have Tony on board, representing Bactiguard and our technology to potential partners as part of our journey towards bringing infection prevention to patients worldwide and profitability to Bactiguard. The Bactiguard infection prevention technology, which is the essence of our company and the foundation of our licensed business, is an ultra-thin coating of the noble metals gold, silver, and palladium. The quantities of the metal are tiny. To put the quantities in perspective, the amount of noble metals equivalent to the size of a pea would coat an entire football or soccer field. When in contact with fluids, the galvanic effect created results in the inhibition of microbe adherence to the surface of medical devices. In the pictures to the right. Taken with an electron microscope. You can see the difference in bacterial colonization between an uncoated surface to the left and a Bactiguard coated surface on the right. The Bactiguard side shows significantly fewer bacteria colonizing, reducing biofilm formation over time and thus leading to lowered rates of infection. Importantly, we believe in evidence. Over the years, a wealth of data has been amassed, all pointing to the effectiveness and safety of our technology. More than 100,000 patients have been part of over 40 clinical trials covering case reports, two randomized controlled trials, and the results have been published in renowned peer-reviewed publications. Our studies cover various patient cohorts, continents and regions, and different therapeutic areas. As we look at the global healthcare trends, our offering is more relevant today than ever. The demand for more effective and safe healthcare solutions is clear. Driven by economic and demographic developments as well as the unfortunate increase in political unrest, conflicts, wars, and natural disasters, there are clear unmet medical needs within the pressing global societal challenges we experience, including healthcare associated infections and antimicrobial resistance. Notably, prevention strategies are, according to the World Health Organization, one of the most important factors in solving these issues. The therapeutic areas we have decided to focus on in our core strategy present huge commercial opportunities for Bactiguard. We see increasing interest in infection prevention strategies, even with our existing partnerships as examples. Urology with BD and orthopedics with Zimmer Biomet. The more we educate the market about our technology, its ability to mitigate infection risk, and how it differentiates partner medical devices, the more confident we are about the joint commercial opportunity. Bactiguard's aim is to seize the significant opportunity presented within each of the strategic therapeutic areas, both with our infection prevention coating technology and the products within the wound management portfolio. The core of our go-forward business model is, as already mentioned, the license business. The most fundamental shift in our 2023 transformation as an organization was going from being production and sales-oriented to knowledge and specialist-focused; stabilized revenues from our partnerships with BD and Zimmer Biomet reflect more collaboration between our organizations, working together as experts, bringing and sharing knowledge with each other. There are still a lot of activities to work on, but we are on the right track when it comes to exploring new partnerships and new applications. We are active across our therapeutic areas with multiple conversations and early testing of our technology with leading medtech companies in the relevant fields. Another crucial part is continuing to build the knowledge and specialist organization. Our core competence areas are in R&D, medical, and regulatory. These all represent critical expertise in collaboration with partners. In essence, the skills and competence needed to bring coated medical devices to the market. With the addition of Thani to our R&D organization, we enhance the combination of innovation and science with business development and have boots on the ground in the US. This is a meaningful step in strengthening our capabilities, with management remaining an important part of the business. Having delivered revenues of approximately 15 million MSEK for Q2 and continuing profitable growth. Now into the details of our partnerships on wound management during the second quarter. BD remains our longest and strongest partner. During the quarter, the transition process for additional markets for Coated Foley catheters continued according to plan, including activities such as training for BD sales and marketing teams across Europe and the Middle East. In these sessions, we shared our knowledge on how to explain the benefits of digital technology to healthcare providers and medical professionals. Doctor Gordon announced in December 2023 that we signed an interim agreement to license additional markets, and that a long-term agreement covering all licensed markets would be signed during the first half of the year. However, back to Bactiguard, BD have jointly agreed to focus primarily on the transition activities, and I want to emphasize that our existing agreements remain in full force. Turning to the Zimmer Biomet collaboration, we are pleased to see the continued market activities across Europe. But the true highlight of the quarter was the introduction of the xenon Bactiguard trauma implant at the annual meeting of the Japanese Society for Fracture Repair in Sendai, Japan. This follows the regulatory approval by the Japanese PMDA obtained in 2023, together with the Zimmer Biomet APAC commercial team. Our Chief Medical Officer and Zimmer Alliance lead were on site to introduce our infection prevention technology to leading orthopedists within the medical community in Japan, we engaged directly with nearly 40 key opinion leaders, both in one-on-one sessions and group meetings, and the Bactiguard technology was included in a presentation by Professor Watanabe to a room of hundreds of delegates. The interest in our technology was clear and underlines the growing recognition of the importance of infection prevention solutions to address critical medical needs in fracture management. While we do not expect significant contributions to revenues from the Japanese market during 2024, this is an important step in the partnership with Zimmer, and the long-term potential is promising. Within the wound management portfolio, we featured our wound healing product line, Hydrocyn aqua, in London at the European Wound Management Association conference in May. EWMA is recognized as the premier international conference for wound care, attracting leading experts, researchers, and healthcare professionals from around the world. Some 5000 attendees were registered on the opening day. We hosted a session on the latest advancements of infection prevention within wound care. The theme was Clean to Heal. Paradigm shift made easy. The interest in the product line Hydrocyn aqua is increasing. The more clinicians understand its mode of action and how it promotes healing and the quality of life for patients with severe wounds. With that, I hand over to Patrick Bach, our CFO, to review our financials in detail.

Patrick Bach
11:26 - 16:48

Thank you, Christine. I am very happy to present our financial results for Q2 and the first half year, with license revenues and EBITINSTDA stabilizing. And to reiterate what Christine mentioned at the beginning of the presentation. We have embarked on our paths towards profitability. Now let's turn to the split of revenues for Q2 and the first half of the year. Our total license revenue amounted to 37.8 million, an increase of 13 million in Q2. Revenues from our long-term partner amounted to 27.6 million, an increase of 9.1 million in Q2. It is worth noting that Q2 last year was a record low quarter for BD, who was reducing their stock levels as previously mentioned. And for the first half year, BD, in total, we saw revenues amounting to 55.6 million and adjusted for currency effects. Revenues increased 1.1% for the first six months. Revenues from Zimmer Biomet amounted to 10.2 million for the quarter, an increase of 5.2 million. These revenues consist of exclusivity revenues related to the orthopedics agreement, as well as license revenues, including minimum royalties related to the trauma agreement. Revenues from Wound Management in Q2 amounted to 14.7 million, an increase of 3.5 million compared to Q2, and for the first half-year, revenues from the Wound Management portfolio amounted to 27.4 million, an increase of 5 million, corresponding to 22.5% growth, with and without currency effects. As Christine mentioned, Wound Management continues on the path of profitable growth. Revenues from BIP amounted to 4.8 million, a decrease of 3.3 million for the quarter. And for the first half years, revenue from the BIP portfolio amounted to 10.9 million, a decrease of 2.3 million. As mentioned, the BIP revenues will continue to decrease as our inventory depletes and we cease production. Other revenues for the quarter amounted to 3.5 million. Within this, we saw currency effects of a positive 1.5 million in revenues. Other revenues for the first half-year amounted to 8.4 million. And currency effects within this amounted to 4.2 million within the first six months. So in total, second quarter revenues amounted to 60.9 million. Adjusted for currency effects of 1.3 million, revenue increased by 16.3% in Q2 and for the first half year. Total revenue amounted to 119.7 million, adjusted for currency effects of 4.7 million. Revenue increased by 2.3%. Now, turning to our operating expenses, our cash flow, and costs for raw materials and consumables amounted to 11.9 million, a decrease of 13.3 million. Other external costs amounted to 19.3 million, Again a decrease of 12 million. Personnel costs amounted to 27.2 million, a decrease of 19.4 million. And other operating expenses amounted to 1.4 million, a decrease of 2.5 million. In total, our total OPEX amounted to 47.8 million, a decrease of 33.9 million. All in all, we are on track to deliver on the cost savings previously announced, exceeding 25 million Swedish Kronor on a yearly basis following the strategic transformation announced last year. Now, turning to the cash flow in Q2, we saw cash flow from operating activities amounted to 16.8 million. Within this, we see changes in working capital for the quarter amounting to 22.1 million. Cash flow from investing activities amounted to -4 million for the quarter. And cash flow from financing activities amounted to -3.3 million for the quarter. In total, cash flow for the second quarter amounted to 9.5 million, and for the first half year to -22.1 million. All in all, cash and cash equivalents at the end of June were up at 105.3 million. With that, I hand back to you, Christine.

Christine Lind
16:50 - 18:30

Thank you, Patrick. To conclude our Q2 presentation, we have a bold, demanding, and inspiring vision to be the global standard of care for preventing medical device-related infections. Achieving this vision requires focus and determination, and these are our priorities ahead. We continue to work on enhancing the business with our current licensed partners, which include BD, Zimmer Biomet, and Well Lead. Simultaneously, we increase interactions and early stage testing of our infection prevention technology together with leading medtech players across our strategic therapeutic areas, aiming to grow our Wound Management portfolio profitably. As I alluded to earlier, we will continue to build our knowledge and specialist organization further to support our partners and deliver on our vision in the best possible way. Nathaniel Bachrach is the most recent example strengthening R&D and business development. We have embarked on the path to sustainable profitability, and we are clearly pleased to deliver a positive EBITDA for the second quarter. License revenues are stabilizing. Operating costs are well under control, and the anticipated cost savings related to the strategic shift from 2023 are on track to be delivered on a full-year basis. While we still have a way to go to deliver on the promise that the Bactiguard technology holds. We can conclude this quarter by being cautiously optimistic about the future for Bactiguard. And with that, we would like to hand over to the operator to open up for questions.

Operator
18:38 - 19:09

If you wish to ask a question, please dial the pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the pound key six on your telephone keypad. The next question comes from Matthias Watson from SEB. Please go ahead.

Matthias Watson
19:11 - 19:45

Hello, this is Matthias from Isabel. I have a few questions today. First one, if you could please update us a bit more on the digital partnership. I'm not sure I fully understood what is happening there. And so when do you expect a sort of long-term agreement to be in place, and how are negotiations proceeding? And also to that question, maybe any sort of insights as to when you expect the revenues to tick up in these expanded markets would be helpful for us. That's the first one.

Christine Lind
19:49 - 21:31

Mrs. Good morning, thank you very much for your questions. I appreciate them very much. In the BD partnership, we have continued to focus in the last quarter and over the last multiple months, now the first six-month period on transitioning the additional markets, which were part of the interim agreement to BD. So there has been quite a lot of activity there. One of the examples is certainly that we have spent time on sales training and marketing training to ensure that our commercial teams are collaborating on the best possible market differentiation and articulation to medical and healthcare professionals to ensure a good uptake of our products in those regions. And our focus here has been primarily on the European and Middle Eastern regions where Bactiguard sold directly prior to our handing over those markets to BD. So that has been the focus here. I do not, however, want to underestimate the value of the BD existing markets. And while we have jointly agreed to focus on the transition activities over the last couple of quarters, our existing agreements do remain in full force. So we're not at all concerned about the timing of a new agreement as the agreements that we have in place do continue in the period. We are quite enthusiastic and remain strongly committed to the BD collaboration as they continue to be our strongest partner and deliver the most revenues to our top line.

Unknown 1
21:34 - 21:34

Good.

Matthias Watson
21:34 - 21:43

So, can you share any insights on when you expect the data revenues to pick up in these expanded markets like Europe and the Middle East?

Patrick Bach
21:45 - 22:44

Hi, Matthias. Thank you for your question. Uh, I appreciate that. As we report now, as you can see, we report a solid revenue number from BD. Now, for the third consecutive quarter. As Christine mentioned, we're very confident about the collaboration with BD. Uh, you're right that with existing and new markets, we should, over time, see growth in the revenues from BD. As we have previously mentioned, we expect the new markets to grow. It will take some time before we see that reflected in the numbers. We definitely have a positive outlook on the future. But as we have communicated before, it will have limited impact on the numbers for this year. We remain confident and optimistic going forward.

Unknown 1
22:45 - 22:45

Good.

Matthias Watson
22:45 - 23:17

Thanks for these answers. The next one is similarly contributing quite strongly here in Q2. If you could go through the magnitude of each income item from this quarter, and share any insights on how you see contributions developing in the second half of the year, I would appreciate it. So that's the second one.

Patrick Bach
23:17 - 24:39

And I appreciate that question. Thank you, Matthias. You're right, we did report an increased amount of revenue from Zimmer Biomet for Q2 in the first half of the year. Uh, uh, in total, 10.2 million, which is a significant increase. In this report, we disclose both the exclusivity revenues and the license revenues, which pertain to royalties, but also to minimum royalties within the trauma agreement. So, as we've communicated before and as outlined in the report, we do have revenues and a revenue stream from Zimmer Biomet that pertains to the exclusivity partnership we have regarding the orthopedics agreement. We do not yet have any products on the market. We have previously communicated when we expect to see any changes. In addition to that, we have the trauma agreement where we do have products in the market across Europe. Um, and for that, we receive royalties. As we have communicated before, we have an agreement around minimum royalties. And that is what we see in the numbers for the first half-year and for Q2.

Unknown 1
24:42 - 24:43

Good.

Matthias Watson
24:43 - 25:08

I will limit myself to three questions to begin with. The next one is, you know, operating expenses (opex) were quite stable from Q1 to Q2, with a slight decrease. So, I guess you are looking for a further decrease in opex ahead to deliver on the 25 million. What are the incremental savings into the second half and maybe a bit on the timing as well?

Patrick Bach
25:09 - 25:50

Um, yes, I appreciate the question. We are, as we said, on track with the development of our total operating expenses. As we saw last quarter and this quarter, they continue to decrease. As communicated earlier, the result of the transformation will be in full force after the first half of this year. So we do expect continued positive developments in our costs, meaning a reduction of the total operating expenses into the coming quarters. At the same time, we are

Unknown 2
25:50 - 25:51

still investing in the business and

Patrick Bach
25:51 - 26:08

strengthening our team. Overall, we are on track to reduce costs exceeding 25 million on a full-year basis.

Unknown 1
26:11 - 26:11

Okay.

Matthias Watson
26:11 - 26:13

Thank you very much for the answers.

Christine Lind
26:14 - 26:14

Thank you. Thank you.

Patrick Bach
26:14 - 26:15

Matthias.

Operator
26:19 - 26:25

The next question comes from Christopher Ledereberg from Carnegie. Please go ahead.

Christopher Ledereberg
26:26 - 26:46

Yeah, thank you. I also have some questions related to the Zimmer Biomet and BD collaboration. To start with Zimmer Biomet, could you provide any update on what they are doing here in Europe? Are they entering new countries, or have they broadened the rollout to include other products being coated?

Christine Lind
26:50 - 28:09

By Christopher, thanks for the question. Great to hear from you. With the Zimmer Biomet collaboration, the rollout across Europe certainly continues. It is a full region that they are ensuring we have continued sales into, and progress is as expected. This is the key market area, I guess I will say where they continue to work. And we do see promise in the future from both Europe and, certainly as we get past the end of 2024 as well, Additional new markets such as Japan, we expect them to continue focusing on new market approvals for trauma products, which is of course Zimmer Biomet, the primary approved product in the region today. Um, and even beyond the trauma collaboration, we also continue our work in recon through a development agreement. And this, of course, refers to the exclusive revenues that Patrick mentioned earlier in that collaboration. So we continue to move forward with new product developments. Um, under our existing agreements with BD, the primary approved product is, of course, the trauma nails.

Christopher Ledereberg
28:13 - 28:20

So, could you comment on how far you are from reaching the minimum royalties?

Unknown 1
28:25 - 28:25

Um.

Patrick Bach
28:25 - 28:57

Hi, Christopher. Uh, Patrick here. Thank you for your question. We report both royalties and minimum royalties within the license revenues. When it pertains to products that are in the market, it will vary from quarter to quarter. So, I cannot specify how much pertains to minimums and how much to actual royalties.

Christopher Ledereberg
29:00 - 29:19

Okay. And then for BD, would we need a new agreement with BD, or how long can we operate under the old one? And would that be sufficient for you in new markets as well?

Christine Lind
29:22 - 30:16

Thanks, Christopher. Uh, great question. We're quite confident in our current collaboration, and our agreements do remain in full force, meaning that we have full market coverage in all global regions, with the exception of China, under the existing agreements with BD. Um, we can continue to focus on the actual activities of commercialization, transitioning markets that were under the interim and extension agreement signed in December, as well as enhancing our efforts to increase activities in existing markets, primarily the US and Japan, without any issues with the contracts. So it is a very good question. Indeed, the agreements do remain in full force and we can focus on the collaboration.

Unknown 3
30:19 - 30:20

Great. Thank will.

Operator
30:27 - 30:56

As a reminder, if you wish to ask a question, please dial Pound Key five on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any written questions or closing comments.

Christine Lind
31:00 - 31:35

Okay. Thank you everyone again for participating. Thanks for the great questions today. They are crucial to us both in our desire to be transparent with the market and to understand what is top of mind for all of you. Please do not hesitate to reach out to Patrick and me, even after the call, with any questions or comments you may have about the business. We are very optimistic about the future of Bactiguard. And we look forward to seeing you on the next quarter's call. Thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…